SBE's First Conference on Accelerating Biopharmaceutical Development   

March 19-22, 2007
Loews Coronado Bay Resort
Coronado Island, California

Technical Session Questionnaire

Survey General Response

Delivering Cost-Effective, Robust Processes and Methods Quickly and Efficiently

As the underlying technology for making antibodies, therapeutic proteins, and vaccines matures, speed and efficiency become more important.  This conference will focus on recent developments (particularly new, "disruptive" technologies) that will be key to accelerating the pace and productivity of biopharmaceutical development.  If you are working on the development and manufacture of biopharmaceuticals such as antibodies, vaccines or therapeutic proteins, you should attend to learn how you can improve your productivity.  Highlighting the meeting is keynote speaker Helen Winkle, Director of the Office of Pharmaceutical Science at the FDA's Center for Drug Evaluation and Research.

The preliminary program  (pdf form) contains further details, including speakers such as Roger Perlmutter, Executive VP of R&D at Amgen, and Anthony Lubiniecki,  VP of Technology Transfer & Project Planning, Centocor.  You can also view the submitted abstracts here.  Conference topics include:

• Rapid cell line development and improved expression system development
• High throughput process, analytical and formulation development
• Emerging "disruptive" technologies
• Technology transfer:  case studies and business practices
• Phase-specific quality systems, quality standards, and analytical comparability studies
• Strategies for production -- in-house or outsourcing options
• Biopharmaceutical development organization and metrics.

If you would like to receive periodic updates regarding this conference, click here and you will be added to our mailing list.

Program
Sponsors and Exhibitors 
Speakers
Organizing Committee